Approximately 20% of the AML patients harbor internal tandem duplication (ITD) mutations in the Fms-like tyrosine kinase-3 (FLT3) gene, which are consistently associated with a poor prognosis [6, 7]. The gene discussed is FLT3; the disease is acute myeloid leukemia.